Novartis Investigative Site

Amarillo, Texas 79124

0 studies enrolling now · 14 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Breast Neoplasms, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Familial Hypercholesterolemia, Heart Failure With Reduced Ejection Fraction, Heart Failure and Reduced Ejection Fraction, Hypertension, Multiple Myeloma, Neoplasms, Breast, Rheumatoid Arthritis, Symptomatic Atherosclerosis

Studies at this site

• ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib — Stopped early
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• 52-104 Week Off-therapy Second Extension to Study CSPP100A2365 — Completed
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. — Stopped early
• An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age — Completed
• Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age — Completed
• NVA237 Versus Placebo 12-week Efficacy Study — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed